Strategic Consulting and Advisory Services
Certara is the largest and most comprehensive provider of biosimulation (modeling and simulation), strategic pharmacometrics, and regulatory writing consulting services. Our multidisciplinary team works alongside clients to inform key drug development decisions and expedite the processes around achieving regulatory milestones.
Software Portfolio: 'End-to-end' Modeling
Certara biosimulation (model based drug development and informatics) software portfolio is the most wide-ranging in the industry. Certara technology is relied upon by over 1,500 biopharm companies and academic institutions for drug research and development.
Certara's Programmatic Consulting Approach Delivers Unquestionable Value to Sponsor Companies
Certara combines its industry renowned pharmacometric and regulatory consultants with our vast software portfolio to provide services that focus on specific outcomes, therapeutic areas, regulatory milestones, and specific populations.
Leading Edge Science: Resource Library
Check out the latest brochures, case studies, white papers, webinars, and more! Search by keywords and/or filter results.
Top 5 Pharma Company Chooses Certara’s D360 as its Global Drug Discovery Platform
June 06, 2014
D360™ will provide enhanced data access and visualization to enable rapid decision making and reduce attrition rates
ST. LOUIS, MO – June 4, 2014 – Certara®, the leading global technology-enabled drug development and drug safety consultancy, announced today that a top 5 Global Pharma company has selected Certara’s D360 as its global drug discovery platform.
D360 is an integrated solution for the query, analysis and visualization of drug discovery and development data. It was selected to overcome the critical challenges familiar to many research organizations today:
- Lack of data connectivity
- The overhead required to learn and support many disparate solutions
- The inefficiency inherent in disconnected workflows
- The challenge in supporting both internal and external collaboration
D360 was selected among many options as the most user-friendly solution to enable key decision-making and support data analysis workflows in a seamless manner.
Jonathan Feldmann, Certara’s Chief Technology Officer, added, “D360 will increase research productivity within this organization by giving scientists a ‘self-service’ data environment, enabling them to search and analyze their data without support from the IT team. Furthermore, D360 will allow them to integrate their analysis workflows with other workflows within Discovery to rapidly answer key questions to accelerate the design cycle and produce better outcomes.”
“Certara is very excited to have another top Pharma company adopt D360 to support global drug research and development,” said James Hayden, Certara’s Senior Vice President of Global Sales and Marketing. “Six of the top 15 pharma companies are now using D360, along with many emerging biotech’s. We are gratified that the industry has responded so strongly to our vision of accelerated R&D through improved access to scientific data and integrated analysis tools.
About Certara
Certara is the leading technology-enabled drug development and drug safety consultancy. Its customers include hundreds of biopharmaceutical companies around the globe, together with several regulatory agencies. Certara’s solutions, which span the discovery, preclinical and clinical stages of drug development, enable data-driven decisions, leading to more precisely designed trials with a reduced risk of failure and improved subject safety. For more information, visit www.certara.com.